Safety, pharmacokinetics and pharmacodynamics after single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) rising oral doses of BIBR 1048 MS/capsules in healthy male subjects of Japanese and Caucasian origin. An Open-label study. Study No. 1160.29. Report no. U06–3091. Boehringer Ingelheim Internal Report - Tomimori, H; Yamamura, N; Adachi, T. (2006)